The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
 
Eric Jonasch
Consulting or Advisory Role - Aveo; Eisai; Exelixis; GlaxoSmithKline; Ipsen; Merck; NiKang Therapeutics; Novartis; Takeda; Telix Pharmaceuticals
Research Funding - Abbvie (Inst); Arrowhead Pharmaceuticals (Inst); Aveo (Inst); Corvus Pharmaceuticals (Inst); Merck (Inst); NiKang Therapeutics (Inst); ProfoundBio (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Elshad Hasanov
Consulting or Advisory Role - Telix Pharmaceuticals
 
Lesley Flynt
No Relationships to Disclose
 
Hyunsoo Hwang
No Relationships to Disclose
 
Rebecca Slack Tidwell
No Relationships to Disclose
 
Roserika Brooks
No Relationships to Disclose
 
Lauren Michelle Wood
No Relationships to Disclose
 
Travis Solley
No Relationships to Disclose
 
Dahlia Mack
No Relationships to Disclose
 
Yuko Yamamura
No Relationships to Disclose
 
Aradhana M. Venkatesan
Honoraria - Pfizer
Research Funding - Toshiba
Travel, Accommodations, Expenses - Pfizer